Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

71.19 +0.56 (+0.79%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance ↗

August 10, 2022

Via Benzinga

Halozyme Therapeutics: Q2 Earnings Insights ↗

August 09, 2022

Halozyme Therapeutics (NASDAQ:HALO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 02, 2022

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact ↗

March 24, 2022

Halozyme Therapeutics Inc (NASDAQ: HALO) has

Via Benzinga

Earnings Scheduled For February 22, 2022 ↗

February 22, 2022

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu...

Via Benzinga

7 Biotech Stocks With Key Catalysts Coming in July ↗

June 27, 2022

Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth.

Via InvestorPlace

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International ↗

May 24, 2022

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.

Via Benzinga

MindMed Appoints Schond L. Greenway As CFO ↗

May 23, 2022

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

Via Benzinga

Recap: Halozyme Therapeutics Q1 Earnings ↗

May 10, 2022

Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Halozyme Therapeutics's Earnings Outlook ↗

May 09, 2022

Halozyme Therapeutics (NASDAQ:HALO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Why Is Sierra Oncology (SRRA) Stock Up Today? ↗

April 13, 2022

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

Via InvestorPlace

Why Antares Pharma Stock Is Soaring Today ↗

April 13, 2022

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing...

Via Benzinga

Why Is Antares Pharma (ATRS) Stock Up Today? ↗

April 13, 2022

Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO).

Via InvestorPlace

Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More ↗

April 13, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗

April 13, 2022

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Via Investor's Business Daily

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13 ↗

April 13, 2022

Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters According to two people with close knowledge of the matter, BlackRock, Inc. (NYSE: BLK) plans to launch...

Via Benzinga

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity ↗

April 13, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

April 13, 2022

Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties ↗

April 08, 2022

Via Benzinga

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗

March 22, 2022

Argenx SE (NASDAQ: ARGX) ) has

Via Benzinga

Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth ↗

February 23, 2022

Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million....

Via Benzinga

Halozyme Therapeutics: Q4 Earnings Insights ↗

February 22, 2022

Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 10, 2021

Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a...

Via Benzinga

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares ↗

December 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...

Via Benzinga

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗

December 07, 2021

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months.

Via InvestorPlace

Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma ↗

December 02, 2021

Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.